Crinetics Pharmaceuticals (CRNX) Income from Continuing Operations (2017 - 2026)

Crinetics Pharmaceuticals' Income from Continuing Operations history runs 10 years deep, the most recent figure standing at 249273000.0 for Q1 2026.

• In Q1 2026, Income from Continuing Operations fell 357.58% year-over-year to 249273000.0; the TTM figure through Mar 2026 stood at 386362000.0 (down 2982.01% YoY), while the FY2025 annual figure was 465317000.0, down 56.18% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 249273000.0, down from 122635000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 115637000.0 in Q2 2025, with the low at 362766000.0 in Q4 2023.
• The 5-year median for Income from Continuing Operations is 42375000.0 (2022), against an average of 20759941.18.
• The sharpest annual moves came in 2022 and 2023: Income from Continuing Operations soared 124.39% in 2022, then slumped 906.31% in 2023.
• Crinetics Pharmaceuticals' Income from Continuing Operations stood at 44991000.0 in 2022, then plunged by 906.31% to 362766000.0 in 2023, then soared by 77.78% to 80595000.0 in 2024, then plunged by 52.16% to 122635000.0 in 2025, then sank by 103.26% to 249273000.0 in 2026.
• Business Quant data shows CRNX's Income from Continuing Operations at 249273000.0 in Q1 2026, 122635000.0 in Q4 2025, and 130091000.0 in Q3 2025.